EGFR and non-small cell lung carcinoma: Osimertinib, the first third-generation EGFR TKI, inhibits both EGFR classical mutations and T790M mutations and demonstrated better efficacy in advanced NSCLC patients with T790M-positive compared with chemotherapy.